Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × monalizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Neoplasms 3 Lung Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Infections 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 COVID-19 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 520 Paclitaxel 472 Cyclophosphamide 467 Docetaxel 411 Capecitabine 348 Letrozole 309 Fulvestrant 268 Doxorubicin 245 Tamoxifen 228 Carboplatin 224 Anastrozole 197 Radiotherapy 193 exemestane 186 Epirubicin 170 Bevacizumab 166 palbociclib 149 Lapatinib 145 Vinorelbine 143 pertuzumab 141 Gemcitabine 138 pembrolizumab 136 Surveys and Questionnaires 118 Exercise 110 Magnetic Resonance Spectroscopy 109 eribulin 103 Fluorouracil 101 Albumin-Bound Paclitaxel 100 Blood Specimen Collection 96 130-nm albumin-bound paclitaxel 90 Everolimus 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04307329 2024-10-22

MIMOSA

The Netherlands Cancer Institute

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡